CD8A and acute myeloid leukemia: According to ELN risk stratification, we found that the EV MFI of CD2, CD8, CD49e, and CD146 from the intermediate-risk AML groups and adverse-risk group (only for CD49e) were significantly reduced in comparison with favorable-risk AML patients (Fig. 4d, e).